Endotel Plus

Uses

Ethinylestradiol & Lynestrenol is used for oral contraception, prevention of pregnancy.

Endotel Plus is also used to associated treatment for these conditions: Menopausal Osteoporosis, Mild to Moderate Acne, Premenstrual Dysphoric Disorder ( PMDD), Moderate Acne vulgaris, Moderate, severe, Vasomotor Symptoms caused by Menopause, Contraception, Folate supplementation therapyEndometrial Carcinoma, Endometrial Hyperplasia, Endometriosis, Hypermenorrhea, Menstrual Distress (Dysmenorrhea), Menstruation, Metrorrhagia, Oligomenorrhoea, Polymenorrhoea, Primary Amenorrhoea, Secondary Amenorrhea, Oral Contraceptives

How Endotel Plus works

Ethinylestradiol is a synthetic estrogenic compound. Use of estrogens have a number of effects on the body including reduced bone density. Combined oral contraceptives suppress ovulation by suppressing gonadotrophic hormone, thickening cervical mucus to prevent the travel of sperm, and preventing changes in the endometrium required for implantation of a fertilized egg. Ethinylestradiol decreases luteinizing hormone, decreasing vascularity in the endometrium. It also increases sex hormone binding globulin.

Dosage

Endotel Plus dosage

Pill is to be taken daily.

Women should be instructed to take the pills at about the same time every day, preferably after the evening meal or at bedtime.

Each subsequent pack is started on the day after the current pack is completed.Continue taking one pill each day.lt is most likely that your menstruation will start while taking the brown pills. Do not discontinue taking the brown pills.

In addition to giving you iron supplementation regular taking of the brown tablets for 7 days will help you keep your pill taking routine.When pt wish period to begin, just stop tablet taking.

While using the second pack woman may have some breakthrough bleeding or spotting. Start with your next pack after the usual 7 day red inactive pill interval.

The advice concerning Management of Missed Pills is applicable. The woman must take the extra active pill(s) needed from a back up pack after vomiting.

Side Effects

Nausea, vomiting, Cholestatic jaundice, Thrombosis, BP rise, Rash, Headache, migraine, mood change, Breast tenderness, pain, enlargement, secretion

Toxicity

Female patients experiencing and overdose may present with withdrawal bleeding, nausea, vomiting, breast tenderness, abdominal pain, drowsiness, and fatigue. Overdose should be treated with symptomatic and supportive care including monitoring for potassium concentrations, sodium concentrations, and signs of metabolic acidosis.

Precaution

Some medications may interfere with the efficacy of the pill. Contact your doctor if you are taking any drugs, such as antibiotics, rifampicin or medicines for seizures. You may have to use another method of contraception during this time.

Interaction

CYP1A2 and CYP3A4 inducers such as aminoglutethimide, carbamazepine, phenobarbital, and rifampin may decrease the effects of estradiol. May enhance the effects of hydrocortisone and prednisolone when used together. Altered anticoagulant effect when used with dicoumarol.

Potentially Fatal: Antibiotics (ampicillin, tetracycline, sulphonamides and chloramphenicol) can cause intermenstrual bleeding or failure of contraception. Reduced efficacy of antihypertensives or hypoglycaemic drugs. Increased metabolism and subsequent reduction in efficacy with enzyme-inducing agents e.g. carbamazepine, griseofulvin, phenobarbital, phenytoin and rifampicin. Adjustment in antidiabetic dose may be required. May increase plasma levels and toxicity of ciclosporin.

Volume of Distribution

A 30µg oral dose has an apparent volume of distribution of 625.3±228.7L and a 1.2mg topical dose has an apparent volume of distribution of 11745.3±15934.8L.

Elimination Route

A 30µg oral dose of ethinylestradiol reaches a C_max of 74.1±35.6pg/mL, with a T_max of 1.5±0.5h, and an AUC of 487.4±166.6pg*h/mL. A 1.2mg dose delivered via a patch reaches a C_max of 28.8±10.3pg/mL, with a T_max of 86±31h, and an AUC of3895±1423pg*h/mL.

Half Life

A 30µg oral dose has a half life of 8.4±4.8h and a 1.2mg topical dose has a half life of 27.7±34.2h.

Clearance

Ethinylestradiol has an intravenous clearance of 16.47L/h, and an estimated renal clearance of approximately 2.1L/h. A 30µg oral dose has a clearance of 58.0±19.8L/h and a 1.2mg topical dose has a clearance of 303.5±100.5L/h.

Elimination Route

Ethinylestradiol is 59.2% eliminated in the urine and bile, while 2-3% is eliminated in the feces. Over 90% of ethinylestradiol is eliminated as the unchanged parent drug.

Pregnancy & Breastfeeding use

Pregnancy Category- X. Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.

Contraindication

Pregnancy, Cardiovascular diseases, Thromboembolic disorders, Severe hypertension, Severe liver disease, Known or suspected estrogen dependent tumor, Endometrial hyperplasia

Innovators Monograph

You find simplified version here Endotel Plus